Sign in
RXRX Stock Price, Chart, Stats & News
Recursion Pharmaceuticals, Inc.
Save
1.48B
Market cap
–
Current P/E
–
Forward P/E
RXRX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | -32.05% |
Operating margin | -869.26% |
Pretax margin | -864.92% |
Net margin | -864.74% |
Effective tax rate | 0.02% |
ROA | -43.74% |
ROE | -63.98% |
D/E | 0.07x |
Interest coverage ratio | -493.63x |
RXRX valuation
P/E | – |
P/S | 17.63x |
P/B | 1.37x |
P/CF | -4.16x |
P/FCF | -3.48x |
P/OCF | -4.16x |
PEG | -0.14x |
EV multiple | -3.53x |
About
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis.
Similar securities
Based on sector and market capitalization
Report issue